HC Wainwright Analysts Increase Earnings Estimates for NKTR

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities researchers at HC Wainwright lifted their Q1 2025 EPS estimates for Nektar Therapeutics in a note issued to investors on Thursday, March 13th. HC Wainwright analyst A. He now forecasts that the biopharmaceutical company will post earnings per share of ($0.15) for the quarter, up from their previous estimate of ($0.17). HC Wainwright has a "Buy" rating and a $6.50 price target on the stock. The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Nektar Therapeutics' Q2 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.68) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at ($0.87) EPS and FY2029 earnings at ($0.52) EPS.

NKTR has been the subject of several other reports. B. Riley initiated coverage on Nektar Therapeutics in a research report on Wednesday, January 8th. They issued a "buy" rating and a $4.00 target price for the company. William Blair reissued a "market perform" rating on shares of Nektar Therapeutics in a report on Thursday, March 13th. Finally, Oppenheimer raised Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $6.00 price target for the company in a report on Friday, March 14th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $4.92.

Remove Ads

Nektar Therapeutics Price Performance

Shares of Nektar Therapeutics stock traded down $0.03 during midday trading on Monday, hitting $0.87. The company had a trading volume of 521,466 shares, compared to its average volume of 1,859,831. The business's 50 day simple moving average is $0.87 and its two-hundred day simple moving average is $1.07. The stock has a market cap of $160.11 million, a PE ratio of -1.03 and a beta of 0.65. Nektar Therapeutics has a 1-year low of $0.65 and a 1-year high of $1.93.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.33. The business had revenue of $29.18 million for the quarter, compared to the consensus estimate of $36.65 million. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%.

Hedge Funds Weigh In On Nektar Therapeutics

Several institutional investors have recently modified their holdings of the stock. Nantahala Capital Management LLC grew its position in shares of Nektar Therapeutics by 90.0% in the 4th quarter. Nantahala Capital Management LLC now owns 7,810,000 shares of the biopharmaceutical company's stock valued at $7,263,000 after purchasing an additional 3,700,000 shares during the period. Woodline Partners LP lifted its stake in Nektar Therapeutics by 187.3% in the 4th quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company's stock valued at $4,626,000 after acquiring an additional 3,242,841 shares in the last quarter. Altium Capital Management LLC lifted its stake in Nektar Therapeutics by 26,172.0% in the 4th quarter. Altium Capital Management LLC now owns 3,000,000 shares of the biopharmaceutical company's stock valued at $2,790,000 after acquiring an additional 2,988,581 shares in the last quarter. 22NW LP bought a new stake in shares of Nektar Therapeutics during the 4th quarter worth approximately $2,038,000. Finally, Eventide Asset Management LLC raised its stake in shares of Nektar Therapeutics by 24.8% during the 3rd quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company's stock worth $12,220,000 after purchasing an additional 1,870,904 shares in the last quarter. 75.88% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Mark Andrew Wilson sold 33,402 shares of the business's stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $0.90, for a total transaction of $30,061.80. Following the completion of the transaction, the insider now directly owns 351,892 shares in the company, valued at approximately $316,702.80. The trade was a 8.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 67,476 shares of company stock worth $64,477 over the last three months. 3.71% of the stock is currently owned by company insiders.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.